Investor Relations

Corporate Profile

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved eye diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Contact Information

Ken Inchausti
Head of Investor Relations & Communications

Receive Email Alerts Email alert icon

Sign up here to receive email alerts whenever Ocugen, Inc. posts new information on the site. Just enter your email address and click Submit.